NCAM-1阳性膜性狼疮性肾炎的临床病理表型与结局
本研究对361例膜性狼疮性肾炎(MLN)患者肾活检标本行NCAM1免疫组化,发现18例(5.0%)肾小球NCAM1阳性。NCAM1阳性组年龄更大、SLEDAI和血肌酐及活动指数更低,抗SSA抗体阳性率更高,治疗反应和ESRD风险无差异,但死亡风险显著更高。
要点
- MLN中肾小球NCAM1阳性率为5.0%(18/361)。
- NCAM1阳性组死亡风险显著高于阴性组(27.8% vs 8.1%,P=.007)。
- 两组治疗反应和ESRD风险无显著差异(P=.668和P=.318)。
核心结论
- 在MLN队列中NCAM1阳性率为5.0%,该亚组患者死亡风险更高,需未来研究验证。
研究设计与样本
- 对连续MLN患者肾活检标本行NCAM1免疫组化,比较NCAM1阳性与阴性患者的临床病理特征及结局,并用蛋白质印迹和间接免疫荧光检测血清抗NCAM1抗体。
主要发现
- 361例MLN中18例(5.0%)肾小球NCAM1阳性。
- NCAM1阳性组年龄35岁(IQR 27-43) vs 28岁(22-37),P=.050。
- NCAM1阳性组SLEDAI 11(IQR 8-12) vs 14(10-18),P=.007。
- NCAM1阳性组血肌酐60 μmol/L(IQR 50-70) vs 70(54-114),P=.029。
- NCAM1阳性组活动指数3(IQR 2-6) vs 6(3-9),P=.045;抗SSA抗体阳性率83.3% vs 58.2%,P=.035。
关键数值与推荐
- NCAM1阳性组与阴性组治疗反应无显著差异(P=.668),ESRD风险无显著差异(P=.318)。
- NCAM1阳性组死亡风险27.8% vs 8.1%(P=.007);匹配后Log-rank P=.013。
- 有血清样本者中1/5(20%)可检出循环抗NCAM1抗体。
临床怎么用
- 对MLN患者可考虑肾活检NCAM1免疫组化识别该亚型,阳性者需关注更高死亡风险。
局限性
- 样本量小(NCAM1阳性仅18例),结论需未来研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No studies have explored the long-term outcomes of neural cell adhesion molecule 1 (NCAM1)-associated membranous lupus nephritis (MLN) patients. METHOD: We performed immunohistochemical studies on kidney biopsy specimens against NCAM1 in consecutive MLN patients. The clinical and histopathological characteristics and outcomes of cases of NCAM1-associated MLN patients are described and compared with NCAM1-negative patients. In addition, we detected serum circulating anti-NCAM1 antibodies through western blotting and indirect immunofluorescence assays. RESULTS: Among 361 MLN cases, 18 (5.0%) were glomerular NCAM1-positive. NCAM1-positive MLN patients were older [35 years (interquartile range, IQR 27-43) versus 28 (22-37); P = .050] and had lower systemic lupus erythematosus disease activity index [11 (IQR 8-12) versus 14 (10-18); P = .007], serum creatinine [60 μmol/L (IQR 50-70) versus 70 (54-114); P = .029] and activity index [3 (IQR 2-6) versus 6 (3-9); P = .045] at kidney biopsy compared with NCAM1-negative patients. The percentage of positive anti-Sjögren's syndrome-related antigen A antibodies in NCAM1-positive patients was significantly greater (83.3% versus 58.2%; P = .035) than in the NCAM1-negative patients. However, no evidence of neuropsychiatric disorders was found in these 18 patients. There were no significant differences in the treatment response and the risk of end-stage renal diseases between NCAM1-positive and -negative groups (P = .668 and P = .318, respectively). However, the risk of death was much higher in the NCAM1-positive group than the NCAM1-negative group (27.8% vs 8.1%; P = .007). Moreover, the risk of death was also much higher in the NCAM1-positive group than the matched NCAM1-negative group (Log-rank P = .013). Additionally, circulating anti-NCAM1 antibodies can be detected in 1/5 (20%) patients who had serum available. CONCLUSION: The prevalence of NCAM1 positivity was 5.0% in our cohort of MLN and the high mortality in these subgroup patients are needed to validate in future studies.
引用
- Xia X, Li S, Jia X, et al. Clinicopathological phenotype and outcomes of NCAM-1+ membranous lupus nephritis. Nephrol Dial Transplant. 2024. PMID: 38991991. doi:10.1093/ndt/gfae148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。